Incyte Corporation vs abrdn Physical Palladium Shares ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while abrdn Physical Palladium Shares ETF trades at $24.83. The key difference: Incyte Corporation is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| INCY | PALL | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.93 | $37.18 |
52-Week Low | $81.61 | $19.96 |
Enterprise Value | $20.04B | — |
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $24.87, down 0.96% over 24 hours. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, though oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a buying opportunity. The ETF provides exposure to physical palladium, which has declined 47% from January 2026 highs.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial demand recovery. Investment opportunity exists if palladium prices rebound from current depressed levels, supported by supply risks and potential catch-up trade. Key risks include continued commodity price volatility, Federal Reserve policy uncertainty, and weaker industrial demand affecting palladium's fundamental drivers.
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →